Patient Preference for Subcutaneous vs. Intravenous Immune Therapy

NCT07223424 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

880

Enrollment

OTHER

Sponsor class

Conditions

Renal Cell Carcinoma
Non Small Cell Lung Cancer
Melanoma
Colo-rectal Cancer (dMMR/MSI-H CRC)
Hepatocellular Carcinoma
Ulcerative Colitis
Esophageal Cancer
Squamous Cell Carcinoma
Gastric/GEJ
Cervical Cancer
Gastro-Esophageal Adenocarcinoma
Esophageal Adenocarcinoma

Interventions

DRUG: nivolumab
DRUG: pembrolizumab

Sponsor

Diwakar Davar